<DOC>
	<DOCNO>NCT01139346</DOCNO>
	<brief_summary>This study Phase I , dose escalation study oral darinaparsin treatment advance solid tumor . Eligible patient could receive amount previous therapy .</brief_summary>
	<brief_title>Study Oral Darinaparsin Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Subjects histological cytological confirmation advance cancer ( solid tumor ) refractory standard therapy condition ; Men woman ≥18 year age ; ECOG performance score ≤2 Eligible subject solid tumor MUST least one measurable lesion define RECIST 1.1 guideline . If measurable disease restrict solitary lesion , neoplastic nature confirm cytology/histology . Measurable lesion MUST NOT previously irradiate field injected biological agent ; Life expectancy ≥12 week ; Adequate bone marrow , liver renal function assess follow laboratory requirement , conduct &lt; 2 week prior Baseline : Creatinine ≤1.5 × upper limit normal ( ULN ) OR calculate creatinine clearance ≥50 cc/min Total bilirubin ≤2 × ULN Alanine transaminase ( ALT ) aspartate transaminase ( AST ) ≤3 × ULN Granulocytes peripheral blood ≥1 × 109/L , hemoglobin ≥10 g/dL , platelet ≥50,000 /µL Adequate vascular access repeat blood sampling ; Men woman childbearing potential must agree use effective contraception Screening duration Study participation ; Written inform consent compliance ZIOPHARM policy Human Investigation Review Committee ( IEC/IRB ) jurisdiction site . Arsenic allergy . New York Heart Association ( NYHA ) functional class ≥3 myocardial infarction ( see Appendix 3 ) within 6 month . Uncontrolled cardiac arrhythmia asymptomatic atrial fibrillation ; QTc ≥450 msec ; ≥Grade 2 atrioventricular ( AV ) block leave bundle branch block ( LBBB ) ; document history prolong QTc . Pregnant and/or lactate woman . Uncontrolled systemic infection ( documented microbiological study ) . Metastatic brain meningeal tumor . Patients seizure disorder require medication ( antiepileptic ) History confusion dementia neurological condition could mask potential adverse response Study Drug , may include transient ischemic attack , Parkinson 's disease , thrombotic hemorrhagic stroke , Alzheimer 's , neurological disorder . Anticancer chemotherapy immunotherapy study within four week Study entry ( mitomycin C nitrosureas give within 6 week Study entry ) Radiotherapy study within 3 week Study entry . Major surgery within 4 week start Study Drug dosing . Other Investigational drug therapy trial within four week prior Study entry . History invasive second primary malignancy diagnose within previous 3 year except Stage I endometrial/cervical carcinoma prostate carcinoma treat surgically , nonmelanoma skin cancer . Substance abuse , medical , psychological , social condition may interfere patient 's participation study evaluation Study result . Any condition unstable could jeopardize safety patient his/her compliance Study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>carcinoma</keyword>
	<keyword>sarcoma</keyword>
	<keyword>metastatic</keyword>
	<keyword>solid tumor</keyword>
</DOC>